Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus with surgery and laser therapy for port-wine macrocheilia and port-wine stains (PLASS-Q)
2024-511937-37-01Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in port-wine stain and vascular malformation, sponsored by Oslo University Hospital. Primary endpoint: Relative change in volume of port-wine macrocheilia from baseline to 60 months. Planned start Jun 2026; status: authorised.
02
Drugs
sirolimus
03
Conditions
port-wine stainvascular malformation
Beyond the preview
Go deeper on 2024-511937-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511937-37-01.